Tuberculosis: 8. The disease in association with HIV infection

CMAJ. Canadian Medical Association Journal

Volumn 161, Issue 1, 1999, Pages 47-51

  FitzGerald, J Mark ^a,c   Houston, Stan ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MINISTRY OF HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CASE REPORT; COUGHING; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SHORT SURVEY; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0033551567     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (48)

1. 1. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis. JAMA 1995;273:220-6.
2. 2. World Health Organization. The world health report 1998. Geneva: The Organization; 1998.
3. 3. FitzGerald JM, Schechter M, Montaner J. The current status of HIV and tuberculosis in Canada. Bull Pan Am Health Organ 1994;117:168-74.
4. 4. Blenkush M, Korzenieska-Kosela M, Elwood RK, Black WA, FitzGerald JM. HIV related tuberculosis in British Columbia: indications of a rise and change in risk groups. Clin Invest Med 1996;19:271-8.
5. 5. FitzGerald JM, Patrick D, Strathdee S. Prevalence of tuberculosis infection in a population of intravenous drug users [abstract]. Am J Respir Crit Care Med 1997;155(Suppl):A561
6. 6. Markowitz N, Hansen NI, Wilcosky TC, Hopewell PC, Glassroth J, Kvale PA, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993;119:185-93.
7. 7. Leroy V, Salmi LR, Dupon M, Sentilhes A, Texier-Maugein J, Dequae L, et al. Progression of human immunodeficiency virus infection in patients with tuberculosis disease. Am J Epidemiol 1997;145:293-300.
8. 8. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995;151:129-35.
9. 9. Goletti D, Weissman D, Jackson RW, Graham NMH, Vlahov D, Klein RS, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996;157:1271-8.
10. 10. Di Perri GD, Danzi MC, De Checchi G, Pizzighella S, Solbiati M, Cruciani M, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989;2:1502-4.
11. 11. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. N Engl J Med 1992;326:231-5.
12. 12. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-50.
13. 13. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137-44.
14. 14. FitzGerald JM, editor. Tuberculosis standards. 4th ed. Ottawa: Canadian Lung Association; 1996.
15. 15. Blenkush M, Kunimoto D, Black W, Elwood RK, FitzGerald JM. Evidence for TB clustering in Vancouver. Results from a pilot study using RFLP. Can Commun Dis Rep 1996;22-7:49-52.
16. 16. Houston S, Ray S, Mahari M, Neill P, Legg W, Latif AS, et al. The association of tuberculosis and HIV infection in Harare, Zimbabwe. Tuberc Lung Dis 1994;75:220-6.
17. 17. FitzGerald JM, Allen EA, Grzybowski S. The impact of human immunodeficiency virus infection on tuberculosis and its control. Chest 1991;100:191-200.
18. 18. Long R, Maycher B, Scalcini M, Manfreda J. The chest roentgenogram in pulmonary tuberculosis patients seropositive for human immunodeficiency virus type 1. Chest 1991;99:123-7.
19. 19. Post EA, Wood R, Pillay GP. Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+ T-lymphocyte count. Tuberc Lung Dis 1995;76:518-21.
20. 20. Jeena PM, Mitha T, Bamber S, Wesley A, Coutsoudis A, Coovadia HM. Effects of the human immunodeficiency virus on tuberculosis in children. Tuberc Lung 1996;77:437-43.
21. 21. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994;72:213-20.
22. 22. Cantwell MF, Snider DE, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994;272:535-9.
23. 23. Tuberculosis morbidity - United States, 1996. MMWR 1997;46:695-700.
24. 24. Schulzer M, Radhamani M, Gryzbowski S, FitzGerald JM. Methodologic issues in the development of a model of the interaction of HIV infection and tuberculosis. Int J Epidemiol 1994;23:400-7.
25. 25. Elliott AM, Namaambo K, Allen BW, Luo N, Hayes RJ, Pobee JOM, et al. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tuberc Lung Dis 1993;74:191-4.
26. 26. Long R, Scalcini M, Manfreda J, Carré G, Philippe E, Hershfield E, et al. Impact of human immunodeficiency virus type 1 on tuberculosis in rural Haiti. Am Rev Respir Dis 1991;143:69-73.
27. 27. Bouza E, Diaz-Lopez, MD, Moreno S, Benaldo de Quirós JCL, Vicente T, Berenguer J. Mycobacterium tuberculosis bacteremia in patients with and without human immunodeficiency virus infection. Arch Intern Med 1993;153:496-500.
28. 28. Tuberculosis Committee, Canadian Thoracic Society. Essentials of tuberculosis control for the practising physician. CMAJ 1994;150:1561-71.
29. 29. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with human immunodeficiency virus. N Engl J Med 1997;337:801-8.
30. 30. Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are are at high risk of tuberculosis. N Engl J Med 1997;337:315-20.
31. 31. Montaner JSG, Phillips P, Zala C, Craib KJP, O'Shaughnessy MV, Schecter MT. Adherence to guidelines for the prevention of HIV related respiratory diseases. Eur Respir J 1996;9:2318-22.
32. 32. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-72.
33. 33. Heal G, Elwood RK, FitzGerald JM. Acceptance and safety of directly observed versus self administered isoniazid preventive therapy in aboriginal peoples in British Columbia. Int J Tuberc Lung Dis 1998;2:979-83.
34. 34. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LJ, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV 1 infection. Lancet 1998;351:786-92.
35. 35. Long R, Fanning A, Cowie R, Hoeppner V, FitzGerald JM. Anti-tuberculous drug resistance in Western Canada. Can Respir J 1997;4:71-6.
36. 36. Casanova J-L, Jouanguy E, Lamhamedi S, Blanche S, Fucher A. Immunological condition of children with BCG disseminated infection [letter]. Lancet 1995;345:581.
37. 37. Health Canada. Management strategies for candidates for protease inhibitors and requiring treatment for Mycobacterium tuberculosis. Can Commun Dis Rep 1998;24:77-80.
38. 38. Clinical update: impact of HIV protease inhibitors on the treatment HIV-infected tuberculosis patients with rifampin. MMWR 1996;45:921-5.
39. 39. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis. JAMA 1998;279:943-8.
40. 40. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995;274:945-51.
41. 41. Volmink J, Garner P. Directly observed therapy. Lancet 1997;349:1399-400.
42. 42. Raistrick D, Hay A, Wolff K. Methadone maintenance and tuberculosis treatment. BMJ 1996;313:925-6.
43. 43. Beirining SE, Huitt GA, Iseman M, Peloquin CA. Malabsorption of anti-tuberculosis medications by a patient with AIDS [letter]. N Engl J Med 1992;327:1817-8.
44. 44. Choudhri SH, Hawken M, Gathua S, Minyiri GO, Watkins W, Sahai J, et al. Pharmokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS and diarrhoea. Clin Infect Dis 1997;25:104-11.
45. 45. Perriens JH, St. Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, et al. Pulmonary tuberculosis in HIV infected patients in Zaire: a controlled trial of treatment for either six or twelve months. N Engl J Med 1995;332:779-84.
46. 46. Chaisson RE, Clermont HC, Holt EA, Cantave M, Johnson MP, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996;154:1034-8.
47. 47. Schluger N, Ciotoli C, Cohen D, Johnson H, Rom WN. Comprehensive tuberculosis control for patients at high risk for tuberculosis. Am J Respir Crit Care Med 1995;151:1486-90.
48. 48. Bayer R. Tuberculosis, public health, and civil liberties. Annu Rev Public Health 1995;16:307-26.